You Searched For "biontech vaccine" and got 20 results
Sort By:
BioNTech plans modular vaccine factories in Africa
Berlin, Feb 16 (AP) German vaccine maker BioNTech, which developed the first widely approved shot a…
Pfizer and BioNTech have started testing an Omicron-specific COVID-19 vaccine for adults
The study will measure the safety and effectiveness of a vaccine tailored to the Omicron variant in…
Jake Epstein
Pfizer and BioNTech surge after the FDA officially approves its COVID-19 vaccine
The vaccine will be marketed under the brand name Comirnaty, and the FDA hopes the approval will nu…
Matthew Fox
BioNTech's CEO says the world might need new COVID-19 vaccines by mid-2022 to protect against emerging variants
Current COVID-19 vaccines and booster shots may not be enough to protect against future variants of…
Kate Duffy
Pfizer and AstraZeneca COVID-19 vaccines less effective against Delta variant, says a Oxford University study
Two doses of either vaccine still provided at least the same level of protection as having had …
PTI
BioNTech has already started developing a new Omicron version of its COVID-19 vaccine
The German biotech, which makes COVID-19 vaccines with Pfizer, said Monday it doesn't want to "wast…
Mary Hanbury
Pfizer, BioNTech ask FDA to authorize two-dose COVID-19 vaccine for children under 5
In a Tuesday press release, the FDA said the agency pushed Pfizer and BioNTech to submit the applic…
Erin Snodgrass
BioNTech soars after COVID-19 vaccine drives monster earnings beat and stronger guidance
BioNTech saw a more than 7,000% jump in revenue year-over-year from €27 million to €2 billion, driv…
Matthew Fox
The FDA's expert panel just gave a thumbs-up for Pfizer's COVID-19 vaccine in younger children, clearing the path for authorization in a matter of days
Younger children between 5 and 11 years old could start getting the Pfizer-BioNTech coronavirus vac…
Andrew Dunn
Moderna, BioNTech tumble 19% amid report the EU is looking into COVID vaccine side effects
The EU's drug regulator is looking at reports about skin rash and kidney problems.
Carla Mozée
The FDA is weighing in on whether to authorize Pfizer's COVID-19 vaccine in younger kids
The data comes as the Food and Drug Administration enters the final stages of reviewing Pfizer's ap…
Andrew Dunn
FDA authorizes boosters of the Pfizer-BioNTech coronavirus vaccine for older adults and others at high risk from COVID-19
The hope is that booster shots will help protect those most at risk as the pandemic continues to ra…
Andrew Dunn
Pfizer-BioNTech COVID-19 vaccine for kids under 5 could be ready by end of February, according to The Washington Post
A Pfizer-BioNTech two-shot regimen for younger kids could be ready in the coming weeks, people brie…
Erin Snodgrass
The Pfizer vaccine's full name is Comirnaty - a hectic mashup of COVID-19, community, immunity, and mRNA
Pfizer's COVID-19 vaccine got full FDA approval on Monday, including of its official name, Comirnat…
Dr. Catherine Schuster-Bruce
Moderna was the most-bought stock for retail traders in the week leading up to its 16% single-day plunge
Wall Street analysts appear less keen than retail traders on vaccine makers such as Moderna, after …
Harry Robertson
The scientist behind Pfizer's vaccine says people will likely need a 3rd COVID-19 shot and yearly doses
BioNTech's chief medical officer said the COVID-19 vaccine would be similar to the annual flu shot …
Natasha Dailey
BioNTech says it will know in 2 weeks whether the COVID-19 vaccine it developed with Pfizer works against the new variant rapidly spreading in southern Africa
The B.1.1.529 variant has been detected in South Africa, Botswana, Hong Kong, and Israel, and it's …
Grace Dean
FDA expected to approve Pfizer-BioNTech's COVID-19 vaccine by early September: NYT
The pharmaceutical company filed its application with the FDA on May 7, and the FDA is expected to …
Azmi Haroun
Moderna and BioNTech stocks are surging amid reports of FDA vaccine-approval progress
Moderna and BioNTech have climbed in recent weeks as the resurgent Delta variant has captured headl…
Ethan Wu
Pfizer climbs after boosting its 2021 COVID-19 vaccine sales forecast by 73%
The company now expects vaccine revenues of around $26 billion, 73% higher than initially projected.